In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May
Are our manufacturing capacity projections adequate for multi-indication expansion
Research shows most people regain two-thirds of lost weight within one year of stopping
Cardiovascular Safety Benefits One of the most encouraging aspects of GLP-1 safety research involves heart health
For a general reconstitution walkthrough covering all peptides, see How to Reconstitute Peptides
How have your hunger levels been lately?" Monica: "Im hungry all the time